ATE521344T1 - Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen - Google Patents
Calciumsalze zur behandlung von psoriasis, dermatitis und schuppenInfo
- Publication number
- ATE521344T1 ATE521344T1 AT05731707T AT05731707T ATE521344T1 AT E521344 T1 ATE521344 T1 AT E521344T1 AT 05731707 T AT05731707 T AT 05731707T AT 05731707 T AT05731707 T AT 05731707T AT E521344 T1 ATE521344 T1 AT E521344T1
- Authority
- AT
- Austria
- Prior art keywords
- dermatitis
- dandruff
- psoriasis
- treatment
- calcium salts
- Prior art date
Links
- 208000001840 Dandruff Diseases 0.000 title abstract 2
- 201000004624 Dermatitis Diseases 0.000 title abstract 2
- 201000004681 Psoriasis Diseases 0.000 title abstract 2
- 159000000007 calcium salts Chemical class 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940050410 gluconate Drugs 0.000 abstract 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 abstract 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 229940066528 trichloroacetate Drugs 0.000 abstract 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000665A ITMI20040665A1 (it) | 2004-04-02 | 2004-04-02 | Sale di calcio per il trattamento della psoriasi e di dermatiti |
| PCT/EP2005/003402 WO2005097084A2 (en) | 2004-04-02 | 2005-03-31 | Calcium salts for the treatment of psoriasis, dermatitis and dandruff |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521344T1 true ATE521344T1 (de) | 2011-09-15 |
Family
ID=34964507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05731707T ATE521344T1 (de) | 2004-04-02 | 2005-03-31 | Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1737439B1 (de) |
| AT (1) | ATE521344T1 (de) |
| CY (1) | CY1112033T1 (de) |
| DK (1) | DK1737439T3 (de) |
| ES (1) | ES2369854T3 (de) |
| IT (1) | ITMI20040665A1 (de) |
| PL (1) | PL1737439T3 (de) |
| PT (1) | PT1737439E (de) |
| SI (1) | SI1737439T1 (de) |
| WO (1) | WO2005097084A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20041279A1 (it) * | 2004-06-24 | 2004-09-24 | Pharmaproducts Uk Ltd | Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico |
| ITMI20041822A1 (it) * | 2004-09-24 | 2004-12-24 | Pharmaproducts Uk Ltd | "agente terapeutico utile per il trattamento di neoplasie plasmacellulari" |
| US20120219596A1 (en) | 2009-07-30 | 2012-08-30 | Wendelin Stark | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| US9023399B2 (en) | 2012-11-16 | 2015-05-05 | NU Technology, LLC | Water-soluble anti-inflammatory cream with natural ingredients base |
| US8613961B1 (en) | 2013-01-09 | 2013-12-24 | NU Technology, LLC | Dermatological cream with natural ingredients base |
| EP2845591A1 (de) * | 2013-09-04 | 2015-03-11 | Polichem S.A. | Verwendung von Trifluoressigsäure als keratolytischer Wirkstoff zur Behandlung hyperkeratotischer Hautläsionen |
| EP3174828B1 (de) * | 2014-07-31 | 2026-03-25 | Amorphical Ltd. | Nichtwässrige flüssige und halbfeste formulierungen von amorphem calciumcarbonat |
| DE102023005341A1 (de) * | 2023-12-22 | 2025-06-26 | Dr. Kurt Wolff Gmbh & Co. Kg | Zusammensetzung umfassend Phosphinsäure und Dimethylglycin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2726187A1 (fr) * | 1994-10-26 | 1996-05-03 | Jean Noel Thorel | Utilisation du calcium par voie topique dans le traitement local des dermatoses hyperproliferatives comme le psoriasis |
| CA2208268A1 (en) * | 1994-12-21 | 1996-06-27 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| ITMI20011495A1 (it) * | 2001-07-12 | 2003-01-12 | Pharmaproducts Uk Ltd | Sali di calcio ad attivita' citotossica |
-
2004
- 2004-04-02 IT IT000665A patent/ITMI20040665A1/it unknown
-
2005
- 2005-03-31 PL PL05731707T patent/PL1737439T3/pl unknown
- 2005-03-31 SI SI200531370T patent/SI1737439T1/sl unknown
- 2005-03-31 EP EP05731707A patent/EP1737439B1/de not_active Expired - Lifetime
- 2005-03-31 WO PCT/EP2005/003402 patent/WO2005097084A2/en not_active Ceased
- 2005-03-31 DK DK05731707.5T patent/DK1737439T3/da active
- 2005-03-31 AT AT05731707T patent/ATE521344T1/de active
- 2005-03-31 PT PT05731707T patent/PT1737439E/pt unknown
- 2005-03-31 ES ES05731707T patent/ES2369854T3/es not_active Expired - Lifetime
-
2011
- 2011-09-27 CY CY20111100930T patent/CY1112033T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112033T1 (el) | 2015-11-04 |
| ITMI20040665A1 (it) | 2004-07-02 |
| EP1737439A2 (de) | 2007-01-03 |
| SI1737439T1 (sl) | 2011-10-28 |
| EP1737439B1 (de) | 2011-08-24 |
| WO2005097084A2 (en) | 2005-10-20 |
| PL1737439T3 (pl) | 2012-01-31 |
| PT1737439E (pt) | 2011-10-21 |
| DK1737439T3 (da) | 2011-11-14 |
| WO2005097084A3 (en) | 2005-12-15 |
| ES2369854T3 (es) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112033T1 (el) | Αλατα ασβεστιου για τη θεραπεια ψωριασης, δερματιτιδας και πιτυριδας | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| IS8505A (is) | (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| ATE548032T1 (de) | Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen | |
| DE60322075D1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| ATE502631T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| RU2008127882A (ru) | Лечение пищевода барретта | |
| ATE525112T1 (de) | Kombination aus flupirtin und tramadaol | |
| EA200701181A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний | |
| NO20033273D0 (no) | Anvendelse av (R)-ibuprofen-metansulfonamid og salter derav til behandlingog forhindring av avstötning av transplanterte organer | |
| ATE488236T1 (de) | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen | |
| DK1970372T3 (da) | Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler | |
| EA200702026A1 (ru) | Лечение или предупреждение зуда | |
| IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
| DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
| DE602005011029D1 (de) | Therapeutisches mittel zur behandlung von plasmazellneoplasien | |
| SE0402636D0 (sv) | Chemical compounds | |
| ATE485820T1 (de) | Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie | |
| MY138165A (en) | Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome | |
| DE602006002126D1 (de) | Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa | |
| ATE464042T1 (de) | Verwendung von neboglamine zur behandlung von schizophrenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1737439 Country of ref document: EP |